Keynote Lectures at Neurotech, China Focus and Alzheimer’s Solutions Conference

FRAMINGHAM, Mass., May 13, 2019 – Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that the company will be making presentations at upcoming industry and investor conferences. The presentations will highlight Alzheon’s scientific discoveries and pioneering Precision Medicine approach to Alzheimer’s disease.

In each of the upcoming Spring presentations, Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon, will present an overview of Alzheon’s lead, Phase-3 ready drug candidate, ALZ‑801, which is a targeted therapy for Alzheimer’s disease.

Event: Neurotech Investing and Partnering Conference

  • Date: Tuesday, May 21, 2019
  • Location: Boston, MA

Event: China Focus Investor Conference

  • Date: Sunday, June 2, 2019
  • Location: Philadelphia, PA

Event: Alzheimer’s Solutions Conference

  • Date: Monday, June 3, 2019
  • Location: Philadelphia, PA

“Alzheon is the frontrunner in developing the first effective treatment for Alzheimer’s that can slow or stop the progression of the disease. Our approach prevents the formation of toxins that can lead to memory loss and drive the onset and progress of Alzheimer’s symptoms. Our safe oral pill ALZ-801 augments the body’s natural mechanism for preventing the formation of these toxins and facilitating clearance from the brain. We are proud to bring new insights to Alzheimer’s and neurological diseases and open the path to develop ALZ-801 as the first drug in a new class of medicines that intervenes in the formation of neurotoxic amyloid oligomers, and offers disease-modifying potential in Alzheimer’s disease,” said Dr. Tolar.

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of beta amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a Precision Medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.


Kathryn Morris
The Yates Network